preloader

558(E)

(Published in Part II, Section 3, Sub Section (ii) of the
Gazette of India Extraordinary)

Government of India
Ministry of Chemicals and Fertilizers
Department of Pharmaceuticals
(National Pharmaceuticals Pricing Authority)

                                                                New Delhi, the 14th March, 2011

 

ORDER

S.O. 558(E)- In exercise of the powers, conferred by sub-paragraph (1)/(2)/(4) of paragraph 8 of the Drugs (Prices Control) Order, 1995, read with No. S.O. 637 (E) dated the 4th September, 1997 issued by the Government of India in the Ministry of Chemicals and Fertilizers, the National Pharmaceutical Pricing Authority, hereby fixes/revises the prices as specified in column (5) of the table hereto annexed as the retail price/revised retail price, exclusive of excise duty, Sales Taxes/VAT and local taxes, if any, and in column (6) as equivalent MRP inclusive of excise duty, education cess, Sales Tax/VAT in relation to each of the formulation specified in the corresponding entry in column (2) of the said table with the pack size specified in the corresponding entries in column (3) thereof; manufactured/imported by M/s. Wockhardt Ltd.

 

Table

Sl. No. Name of the formulation Pack   Size  Existing  Retail  Price  (Rs.) Retail Price without   Excise Duty and Local Tax, if any  (Rs.) Equivalent MRP*  inclusive  of all taxes  (Rs.)
 (1)  (2)  (3)  (4)  (5)  (6)
1. Wosulin R 40 IU Each ml Isophane suspension contain Human Insulin – 40 IU M- Cresol 0.25% w/v (as preservative) 10ml    Vial 120.08 135.12   145.55
2.

 Wosulin N 40 IU   Each ml Isophane suspension containHuman Insulin – 40 IU

M- Cresol 0.25% w/v (as preservative)

Phenol 0.065% w/v (as preservative)

10ml    Vial 120.10  135.22   145.66
3.

Wosulin 50/50 Each ml contain

Human Insulin – 40 IU

(50% solube insulin injection &

50% Isophane Insulin Injection)

M- Cresol 0.16% w/v (as preservative)

Phenol 0.065% w/v (as preservative)

10ml  Vial 120.10  135.24 145.68
4.

 Wosulin 30/70    Each ml contain

Human Insulin – 40 IU

(30% solube insulin injection &

70% Isophane Insulin Injection)

M- Cresol 0.16% w/v (as preservative)

Phenol 0.065% w/v (as preservative)

10ml   Vial 120.10  135.18  145.62
5.

Wosulin N 100IU/ml   Each ml of isophane

suspension contain

Insulin Human USP 100IU

M-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

3ml Cartridge with Glass Ball 133.12   145.54 156.78
6. Wosulin R 100IU/ml  Each ml contain Insulin Human USP 100IU  M-cresol USP 0.25% w/v preservative 3ml Cartridge  with Glass Ball 133.10 144.22 155.35
7.

 Wosulin 50/50 100IU/ml   Each ml contain

Insulin Human USP 100IU

(50% Insulin Human neutral and 50% Isophane Insulin)

M-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

3ml Cartridge  with Glass Ball 134.34  145.54 156.78
8.

Wosulin 30/70 100IU/ml  Each ml containInsulin Human USP 100IU

(30% Insulin Human neutral and

70% Isophane Insulin)

M-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

3ml Cartridge with Glass Ball  134.34 145.54 156.78
9.

 Wosulin N Dispo Pen Each ml contain Insulin Human USP 100IUM-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

3ml Cartridge with Disposable  Pen 225.24  237.68  256.03
10.  Wosulin R Dispo Pen   Each ml contain Insulin Human USP 100IU  M-cresol USP 0.25% w/v preservative   3ml Cartridge   with Disposable  Pen  225.26 236.38   254.63
11.

Wosulin 50/50 Dispo Pen Each ml contain   Insulin Human USP 100IU(50% Insulin Human neutral and

50% Isophane Insulin)

M-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

3ml Cartridge  with Disposable Pen &Glass Ball 226.48 237.68 256.03
12.

Wosulin 30/70 Dispo Pen   Each ml contain   Insulin Human USP 100IU (30% Insulin Human neutral and

70% Isophane Insulin)

M-cresol USP 0.16% w/v preservative

Phenol IP 0.065% w/v preservative

  3ml Cartridge  with Disposable  Pen & Glass Ball   226.48 237.68 256.03”

*Subject to actual payment of Government levies/taxes, as applicable.

 

NOTE :

  1. The prices fixed are the maximum retail prices in column no. (6) (inclusive of excise duty, sales tax/VAT and local taxes if any) for the specified pack and packs of similar strength, and companies cannot claim exemption on any ground there from, unless specifically permitted by the Government/NPPA through an order.
  2. The companies / manufacturers may added taxes only if they have paid actually to the Government on the price mentioned in the column (5).  If there is any variation in the MRP (inclusive of the taxes), the same may be intimated to the NPPA in the Form-V of DPCO, 1995.
  3. For different packing material used or, different drug delivery systems or any other special features/forms claimed, the retail prices, as specified in Column No. 5 above, shall be applicable unless the companies approaches NPPA for specific price approvals for its formulations.
  4. The manufacturer and marketing company for the above said formulation shall be required to take the requisite prior approval from the competent Authority for any change in the composition of the above said formulation with written prior intimation to the National Pharmaceutical Pricing Authority.
  5. These prices/revised prices shall be made effective within 15 days of receipt of this order as required under sub para 14(1) of DPCO, 1995. The necessary price-list should also be issued as required under sub-paragraph (3) of paragraph 14 of the Drugs (Prices Control) Order, 1995.
  6. These prices fixed/notified hereinabove under the provisions of DPCO, 1995 have to be mandatorily implemented by the manufacturing/marketing company notwithstanding its status of compliance of conditions for such formulation pack under the Drugs and Cosmetics Act, 1940.
  7. The manufacturer or marketing company not complying with the ceiling prices and conditions specified in notes hereinabove within 15 days from the date of above said notification, shall be liable to deposit overcharged amount along with the interest under the provisions of the DPCO, 1995 read with the EC Act, 1955.

PN/118/2011/F

F. No. 8(27)/2011/D.P./NPPA-Div.II

(MANISH GOSWAMI)
Deputy Director

Last Page Updated: 07-02-2019